Home › Alopecia Areata
Alopecia Areata clinical trials recruiting in the U.S.
16 studies for Alopecia Areata are recruiting participants at sites across the United States.
Cities with the most studies
- Indianapolis, IN7 studies
- Miami, FL6 studies
- San Antonio, TX6 studies
- Omaha, NE5 studies
- New York City, NY5 studies
- Irvine, CA4 studies
- Round Rock, TX3 studies
- Los Angeles, CA3 studies
- Troy, MI3 studies
- Chicago, IL3 studies
- Houston, TX3 studies
- Portland, OR3 studies
- Columbus, OH3 studies
- Evanston, IL3 studies
By state
- California9 studies
- Florida8 studies
- Illinois5 studies
- Indiana7 studies
- Maryland5 studies
- Massachusetts4 studies
- Michigan5 studies
- Nebraska5 studies
- New York6 studies
- Ohio6 studies
- Oregon3 studies
- Pennsylvania3 studies
- South Carolina3 studies
- Texas7 studies
- Washington3 studies
Recently updated studies
Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
RecruitingPhase 2Healthy volunteers welcome
Ages 12 to 75 · All sexes · Updated Nov 6, 2026 · NCT05398809A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
RecruitingPhase 2
Ages 18 to 60 · All sexes · Updated Nov 4, 2026 · NCT07533006A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
RecruitingPhase 3
Ages 6 to 17 · All sexes · Updated Oct 27, 2026 · NCT07772492A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Oct 26, 2026 · NCT07733765A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Oct 20, 2026 · NCT06873945A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
RecruitingPhase 3
Ages 12 to 63 · All sexes · Updated Oct 19, 2026 · NCT06012240Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Oct 16, 2026 · NCT07242638A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
RecruitingPhase 3
Ages 6 to 14 · All sexes · Updated Oct 15, 2026 · NCT07029828HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata
RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Sep 15, 2026 · NCT07049328Dupilumab in the Treatment of Pediatric Alopecia Areata
RecruitingPhase 2
Ages 6 to 17 · All sexes · Updated Sep 2, 2026 · NCT05866562CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry
RecruitingObservational study
Ages 12 to 17 · All sexes · Updated Aug 17, 2026 · NCT06562270Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Jun 26, 2026 · NCT06747611Regeneron AA Multicenter (Dupilumab)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 17, 2026 · NCT05551793A Study of LAD603 in Adults With Alopecia Areata
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated May 20, 2026 · NCT07311564CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry
RecruitingObservational study
Ages 18 and older · All sexes · Updated Feb 9, 2026 · NCT05745389Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
RecruitingPhase 3
Ages 12 to 17 · All sexes · Updated Jan 28, 2026 · NCT07133308From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.